Zobrazeno 1 - 10
of 49
pro vyhledávání: '"Alan P. Venook"'
Autor:
Demetris Papamichael, Guilherme S. Lopes, Curt L. Olswold, Jean-Yves Douillard, Richard A. Adams, Timothy S. Maughan, Eric Van Cutsem, Alan P. Venook, Heinz-Josef Lenz, Volker Heinemann, Richard Kaplan, Carsten Bokemeyer, Benoist Chibaudel, Axel Grothey, Takayuki Yoshino, John Zalcberg, Aimery De Gramont, Qian Shi
Publikováno v:
European Journal of Cancer. 163:1-15
Colorectal cancer (CRC) affects many older adults. We investigated the efficacy and safety of adding anti-epidermal growth factor receptor (EGFR) agents to doublet chemotherapy (DC) in older patients.Patients with RAS wild-type (WT) metastatic CRC (m
Autor:
Federico Innocenti, Akram Yazdani, Naim Rashid, Xueping Qu, Fang-Shu Ou, Scott Van Buren, Monica M. Bertagnolli, Omar Kabbarah, Charles David Blanke, Alan P. Venook, Heinz-Josef Lenz, Benjamin G. Vincent
Publikováno v:
Clin Cancer Res
Purpose: CALGB/SWOG 80405 was a randomized phase III trial in first-line patients with metastatic colorectal cancer treated with bevacizumab, cetuximab, or both, plus chemotherapy. We tested the effect of tumor immune features on overall survival (OS
Autor:
Andrew B. Nixon, Alexander B. Sibley, Yingmiao Liu, Ace J. Hatch, Chen Jiang, Flora Mulkey, Mark D. Starr, John C. Brady, Donna Niedzwiecki, Alan P. Venook, Luis Baez-Diaz, Heinz-Josef Lenz, Bert H. O'Neil, Federico Innocenti, Jeffrey A. Meyerhardt, Eileen M. O'Reilly, Kouros Owzar, Herbert I. Hurwitz
Publikováno v:
Clinical Cancer Research. 28:2779-2788
Purpose: CALGB 80405 compared the combination of first-line chemotherapy with cetuximab or bevacizumab in the treatment of advanced or metastatic colorectal cancer (mCRC). Although similar clinical outcomes were observed in the cetuximab-chemotherapy
Autor:
Osvaldo Espin-Garcia, Geoffrey Liu, Kouros Owzar, Maura N Dickler, Monica M. Bertagnolli, Danyu Lin, Chen Jiang, Amy S. Etheridge, Federico Innocenti, Alan P. Venook, Heinz-Josef Lenz, Hedy L. Kindler, Mark J. Ratain, Jin Wang, Alexander B. Sibley, Wei Xu, Julia C F Quintanilha
Publikováno v:
Int J Cancer
Germline variants might predict cancer progression. Bevacizumab improves overall survival (OS) in patients with advanced cancers. No biomarkers are available to identify patients that benefit from bevacizumab. A meta-analysis of genome-wide associati
Autor:
Radia M. Johnson, Xueping Qu, Chu-Fang Lin, Ling-Yuh Huw, Avinashnarayan Venkatanarayan, Ethan Sokol, Fang-Shu Ou, Nnamdi Ihuegbu, Oliver A. Zill, Omar Kabbarah, Lisa Wang, Richard Bourgon, Felipe de Sousa e Melo, Chris Bolen, Anneleen Daemen, Alan P. Venook, Federico Innocenti, Heinz-Josef Lenz, Carlos Bais
Publikováno v:
Nature communications. 13(1)
Most colorectal (CRC) tumors are dependent on EGFR/KRAS/BRAF/MAPK signaling activation. ARID1A is an epigenetic regulator mutated in approximately 5% of non-hypermutated CRC tumors. Here we show that anti-EGFR but not anti-VEGF treatment enriches for
Autor:
Federico Innocenti, Priya Jayachandran, Daniel Magee, Wu Zhang, Phillip Stafford, Francesca Battaglin, Richard M. Goldberg, Hiroyuki Arai, Anthony F. Shields, Andrew Elliott, Aaron Scott, Emil Lou, Jian Zhang, Shivani Soni, Jimmy J. Hwang, Jim Abraham, Moh’d Khushman, Jingyuan Wang, Benjamin A. Weinberg, Alan P. Venook, Davendra Sohal, Albert C. Lockhart, Fang-Shu Ou, Heinz-Josef Lenz, Michael J. Hall, W. Michael Korn, Joshua Millstein, Natsuko Kawanishi, Joanne Xiu
Publikováno v:
Oncogene
Loss-of-function alterations of Neurofibromin 1 (NF1) activate RAS, a driver of colorectal cancer. However, the clinical implications of NF1 alterations are largely unknown. We performed a comprehensive molecular profiling of NF1-mutant colorectal ca
Autor:
Jun Yin, Matthew T. Seymour, Axel Grothey, Aimery de Gramont, Thierry André, Eduardo Diaz Rubio, Benoist Chibaudel, Alfredo Falcone, Heinz-Josef Lenz, Eric Van Cutsem, Volker Heinemann, Cornelis J A Punt, Zhaohui Jin, Tim Maughan, Richard Kaplan, Romain Cohen, Richard Adams, John Zalcberg, Carsten Bokemeyer, Takayuki Yoshino, Qian Shi, Alan P. Venook, Levi Pederson, Miriam Koopman, Niall C. Tebbutt, Heshan Liu
Background Unplanned subgroup analyses from several studies have suggested primary tumor sidedness (PTS) as a potential prognostic and predictive parameter in metastatic colorectal cancer (mCRC). We aimed to investigate the impact of PTS on outcomes
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2557db80e3d7b8e1034562b8847a27e5
Association of Coffee Intake With Survival in Patients With Advanced or Metastatic Colorectal Cancer
Autor:
Kimmie Ng, Jeffrey A. Meyerhardt, Chen Yuan, Heinz-Josef Lenz, Christopher Mackintosh, Richard M. Goldberg, Eileen M. O'Reilly, Robert J. Mayer, Sui Zhang, Fang-Shu Ou, Federico Innocenti, Donna Niedzwiecki, Andrew B. Nixon, Brian C. Mullen, I-Wen Chang, Bert H. O'Neil, Alan P. Venook, Charles S. Fuchs, Charles D. Blanke
Publikováno v:
JAMA Oncol
Importance Several compounds found in coffee possess antioxidant, anti-inflammatory, and insulin-sensitizing effects, which may contribute to anticancer activity. Epidemiological studies have identified associations between increased coffee consumpti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::34da393c5dd59906d5c052bda37ddb56
https://europepmc.org/articles/PMC7499248/
https://europepmc.org/articles/PMC7499248/
Autor:
Alexander B. Sibley, Chen Jiang, Monica M. Bertagnolli, Fang-Shu Ou, Alan P. Venook, Sarah J. Plummer, Stefanie D. Howell, Graham Casey, Yoichi Furukawa, Joel S. Parker, Mark J. Ratain, Federico Innocenti, Amy S. Etheridge, Howard L. McLeod, Heinz-Josef Lenz, Kouros Owzar, James Todd Auman, Michiaki Kubo, Sushant A. Patil, Charles D. Blanke
Publikováno v:
Clin Cancer Res
Purpose: Irinotecan/5-fluorouracil (5-FU; FOLFIRI) or oxaliplatin/5-FU (FOLFOX), combined with bevacizumab or cetuximab, are approved, first-line treatments for metastatic colorectal cancer (mCRC). We aimed at identifying germline variants associated
Autor:
Scott Van Buren, Akram Yazdani, Benjamin G. Vincent, Charles D. Blanke, Omar Kabbarah, Alan P. Venook, Heinz-Josef Lenz, Federico Innocenti, Xueping Qu, Fang-Shu Ou
Publikováno v:
Journal of Clinical Oncology. 39:3515-3515
3515 Background: CALGB/SWOG 80405 was a randomized phase III trial in first-line mCRC patients treated with Bev, Cet, or both, plus chemotherapy. No difference in OS was found between Bev and Cet. We tested the effect of immune signatures on OS in al